Composition for tissue repair comprising biodegradable polymer and DNA fragment mixture
A biodegradable polymer and DNA fragment mixture in tissue repair compositions addresses rapid degradation and inflammatory issues, ensuring stable suspension and enhanced collagen production for long-term tissue repair and improved cosmetic outcomes.
Patent Information
- Application Number
- PCT/KR2026/005200
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2026-02-11
- Filing Date
- 2026-04-06
- Publication Date
- 2026-11-19
AI Technical Summary
Existing tissue repair compositions using biodegradable polymers face issues with rapid degradation, inflammatory responses, and poor dispersibility, leading to short-term effectiveness and cosmetic side effects like nodules and clumping.
A tissue repair composition comprising a mixture of biodegradable polymers and DNA fragments, which stabilizes the suspension, reduces inflammatory responses, and promotes collagen production, enhancing long-term tissue repair and cosmetic improvement without using dispersants like CMC or hyaluronic acid.
The composition maintains pH stability, reduces inflammatory reactions, ensures uniform distribution of biodegradable polymer microparticles, and increases collagen production, resulting in improved biocompatibility and long-term tissue repair with reduced side effects.
Smart Images

Figure KR2026005200_19112026_PF_FP_ABST
Abstract
Description
Tissue repair composition comprising a mixture of biodegradable polymers and DNA fragments
[0001] The present invention relates to a tissue repair composition comprising a mixture of a biodegradable polymer and a DNA fragment.
[0002]
[0003] As interest in appearance, including the face and body, increases, there is a growing number of cosmetic skin procedures aimed at improving skin condition and addressing aesthetic deficiencies. In particular, there is rising interest in procedures designed to improve skin wrinkles and other external skin conditions. Recently, alongside cosmetic purposes, methods involving the injection of substances similar to skin tissue—so-called tissue-repairing compositions (fillers)—into desired body parts for medical purposes, such as replacing damaged biological tissue, are being widely practiced. In this context, tissue-repairing compositions (fillers) play a role in correcting skin imperfections and, in particular, improving the skin's appearance by restoring volume beneath sunken skin caused by facial wrinkles or scars.
[0004] Hyaluronic acid, a component of tissue repair compositions, is a biopolymer that exists in the body and is widely used in medical and cosmetic applications due to its excellent biocompatibility. However, since hyaluronic acid itself degrades within a few hours, limiting its application, research has been conducted to enhance its persistence in the body through cross-linking. Increasing the content of the cross-linking agent during manufacturing to extend the duration of hyaluronic acid in the body can lead to inflammatory reactions because the agent is recognized as a foreign substance within the body. Conversely, reducing the content of the cross-linking agent results in a material with low viscoelasticity and rapid degradation within the body.
[0005]
[0006] Since the development of tissue repair compositions that provide excellent biocompatibility, reasonably long-lasting durability, and the ability to form a refined and natural shape after injection is insufficient, the development of improved tissue repair compositions is still required.
[0007]
[0008] One objective of the present invention is to provide a tissue repair composition comprising a mixture of a biodegradable polymer and a DNA fragment.
[0009] Another objective of the present invention is to provide a composition for inhibiting or mitigating oxidation of a biodegradable polymer, comprising the above composition as an active ingredient.
[0010] Another objective of the present invention is to provide a method for preparing the tissue repair composition.
[0011] Another objective of the present invention is to provide a tissue repair method comprising the step of administering the composition to an individual.
[0012] Another objective of the present invention is to provide a tissue repair use of the above tissue repair composition.
[0013]
[0014] The tissue repair composition according to the present invention comprises a mixture of a biodegradable polymer and a DNA fragment, thereby having the effect of suppressing rapid acidification caused by a decrease in pH and reducing inflammatory responses compared to the case where a composition composed solely of a biodegradable polymer is used. Furthermore, even without using dispersants such as CMC or hyaluronic acid (HA), the dispersibility of biodegradable polymer microparticles and suspension stability within the syringe are superior to comparative examples using such dispersants, thereby reducing nodule formation or clumping after injection. Moreover, the composition of the present invention provides a tissue repair formulation with excellent biocompatibility that promotes collagen production and tissue regeneration, contributing to long-term tissue repair and cosmetic improvement rather than merely volume formation.
[0015]
[0016] FIGS. 1 to 5 are graphs showing the change in pH over time of an example composition containing PN and a comparative example composition not containing PN.
[0017] Figures 6 to 8 are graphs comparing pH change patterns according to the presence or absence of PN, depending on the type and content conditions of the biodegradable polymer.
[0018] Figure 9 is a graph showing the change in the number of inflammatory cells over time between an example composition containing PN and a comparative example composition (commercial product) that does not contain PN.
[0019] Figure 10 is a graph comparing the effect of changes in PN content by comparing the change in the number of inflammatory cells according to the type and content conditions of biodegradable polymers.
[0020] FIGS. 11 and 12 are SEM and / or cryo-SEM images showing the dispersion state of biodegradable polymer microparticles in a composition containing PN and a composition not containing PN.
[0021] FIG. 13 is an SEM image or graph showing the particle size distribution including the minimum and maximum particle diameters of the biodegradable polymer microparticles used in the present invention.
[0022] Figure 14 is a graph comparing the injection force according to the injection location of an example composition containing PN and a comparative example composition containing CMC or HA.
[0023] Figure 15 is a graph comparing the injection power of the PN-containing composition and the comparative example composition according to the type and content of the biodegradable polymer.
[0024] FIGS. 16 to 24 are photographs showing the homogeneity (suspension) within a syringe over time after filling a syringe with an example composition and a comparative example composition containing PN.
[0025] Figure 25 is a diagram comparing the change in nodule or protrusion height between the PN-containing example composition and the PN-free commercial product over time through a 3D image of the skin surface taken with a PRIMOS device after injecting the composition into the subcutaneous tissue of a mouse.
[0026] Figure 26 is a graph comparing the ratio of collagen staining area between an example composition containing PN and a comparative example composition not containing PN.
[0027] Figure 27 is a graph showing the staining results of collagen production ability between an example composition containing PN and a commercially available product that does not contain PN.
[0028]
[0029] This is explained in detail as follows. Meanwhile, each description and embodiment disclosed in the present invention may be applied to each other description and embodiment. That is, all combinations of the various elements disclosed in the present invention fall within the scope of the present invention. Furthermore, the scope of the present invention should not be considered limited by the specific descriptions provided below.
[0030] Furthermore, a person skilled in the art can recognize or identify a number of equivalents to the specific embodiments of the present invention described in this invention using only ordinary experiments. In addition, such equivalents are intended to be included in the present invention.
[0031]
[0032] One aspect of the present invention provides a tissue repair composition comprising a mixture of a biodegradable polymer and a DNA fragment as an active ingredient.
[0033] In one embodiment, the biodegradable polymer may be included in an amount of 0.5% to 40% by weight based on the total weight of the composition, and the diameter of the biodegradable polymer particles may be 10 μm to 60 μm.
[0034] In the present invention, “biodegradable polymer” refers to a type of polymer that can be degraded by biological action.
[0035]
[0036] In one embodiment, the biodegradable polymer may be one or more selected from the group consisting of polycaprolactone (PL), polylactic acid (PLA), polyglycolic acid (PGA), poly(lactic-co-glycolic acid) (PLGA), poly(dioxanone) (PDS), dioxanone-caprolactone copolymer, lactic acid-caprolactone copolymer, and mixtures thereof, wherein polylactic acid (PLA) is a general term including Poly-L-lactic acid (PLLA), Poly-D,L-lactic acid (PDLLA), and Poly-D-lactic acid (PDLA), unless otherwise noted. As a specific example, the biodegradable polymer may be poly(lactic-co-glycolic acid), PLGA, but is not limited thereto.
[0037] The above biodegradable polymer may be included in an amount of 0.5% to 40% by weight based on the total weight of the composition. Specifically, the biodegradable polymer may be included in an amount of 0.5% to 40% by weight, and more specifically, 0.5% to 40% by weight, 0.5% to 35% by weight, 0.5% to 30% by weight, 0.5% to 25% by weight, 0.5% to 20% by weight, 0.5% to 15% by weight, 0.5% to 10% by weight, 1% to 40% by weight, 1% to 35% by weight, 1% to 30% by weight, 1% to 25% by weight, 1% to 20% by weight, 1% to 15% by weight, 1% to 10% by weight, 2% to 40% by weight, 2% to 35% by weight, 2% to 30% by weight, 2% to 25% by weight. The amount may be 2% to 20% by weight, 2% to 15% by weight, 2% to 10% by weight, 4% to 40% by weight, 4% to 35% by weight, 4% to 30% by weight, 4% to 25% by weight, 4% to 20% by weight, 4% to 15% by weight, or 4% to 10% by weight. More specifically, the biodegradable polymer may be included in an amount of about 0.5% by weight, about 1% by weight, about 2% by weight, about 3% by weight, about 4% by weight, about 5% by weight, about 10% by weight, about 15% by weight, about 20% by weight, about 25% by weight, about 30% by weight, about 35% by weight, or about 40% by weight, but is not limited thereto.
[0038] In addition, the diameter of the particles of the biodegradable polymer may be 10 μm to 60 μm based on the average particle diameter. Specifically, the average particle diameter of the biodegradable polymer may be 10 μm to 60 μm, 10 μm to 55 μm, 10 μm to 50 μm, 10 μm to 45 μm, 10 μm to 40 μm, 10 μm to 35 μm, 10 μm to 30 μm, 10 μm to 25 μm, 10 μm to 20 μm, 15 μm to 60 μm, 15 μm to 55 μm, 15 μm to 50 μm, 15 μm to 45 μm, 15 μm to 40 μm, 15 μm to 35 μm, 15 μm to 30 μm, 15 μm to 25 μm, or 15 μm to 20 μm, and more specifically, about 10 μm, about It may be 15 μm, about 20 μm, about 25 μm, about 30 μm, about 35 μm, about 40 μm, about 45 μm, about 50 μm, about 55 μm, or about 60 μm, but is not limited thereto.
[0039]
[0040] In the present invention, the term "DNA fragment mixture" refers to a mixture of nucleic acid fragments with a molecular weight of a certain range, existing as a polymer of nucleotides, comprising DNA corresponding to a biopolymer composed of phosphate, four types of bases, and deoxyribose. The DNA fragment mixture may exist in the form of fragments with reduced molecular weight, but is not limited thereto, and may be used interchangeably with terms such as "DNA fragment," "DNA fraction," "nucleic acid fragment," and "nucleic acid fragment mixture."
[0041] In one embodiment, the DNA fragment mixture may be one or more selected from the group consisting of polydeoxyribonucleotide (PDRN), polynucleotide (PN), and mixtures thereof.
[0042] In the present invention, the term "polynucleotide" is referred to as "PN" and may refer to a DNA or RNA strand, which is a polymer of nucleotides in which nucleotide monomers are linked in a chain shape by covalent bonds. In the present invention, the term "polydeoxyribonucleotide" is also referred to as "PDRN" and may be a type of low molecular weight DNA complex having a specific molecular weight, but is not limited thereto. For example, the polynucleotide may have a relatively longer nucleic acid length or a larger molecular weight compared to the polydeoxyribonucleotide, and may be used as a raw material for medical devices for cell adhesion, lubrication, and buffering effects as a physical support, and the polydeoxyribonucleotide may be used as a raw material for pharmaceuticals for cell proliferation and tissue regeneration, but is not limited thereto.
[0043] In an embodiment according to any one of the preceding embodiments, the liquid formulation of the DNA fragment mixture of the present invention may comprise one or more solvents selected from the group consisting of sterile distilled water, water for injection, and a buffer solution, and the aforementioned buffer solution may be one or more selected from the group consisting of sodium phosphate monobasic dihydrate, sodium phosphate dibasic dodecahydrate, potassium dihydrogen phosphate, sodium chloride, magnesium chloride, potassium chloride, phosphate buffered saline, and HEPES (N-(2-hydroxyethyl)-piperazine-N'-2-ethanesulfonic acid) and mixtures thereof, but is not limited thereto.
[0044] In an embodiment according to any one of the preceding embodiments, the DNA fragment mixture of the present invention may be in the form of a salt containing sodium, specifically, polynucleotide sodium and / or polydeoxyribonucleotide sodium, but is not limited thereto.
[0045] In an embodiment according to any one of the preceding embodiments, the DNA fragment mixture of the present invention may be obtained by extracting from the testes or semen of a fish. Specifically, the fish may be a salmonid fish. More specifically, it may be a salmon or a trout, but is not limited thereto.
[0046] In an embodiment according to any one of the preceding embodiments, the DNA fragment mixture of the present invention may have a molecular weight of about 1 to 100,000 kDa, 5 to 50,000 kDa, 50 to 10,000 kDa, or 50 to 1,500 kDa.
[0047] As one embodiment of the above-described embodiment, the DNA fragment mixture of the present invention may be a polynucleotide (PN), but is not limited thereto.
[0048] The above DNA fragment mixture may be included in an amount of 0.5% to 4% by weight based on the total weight of the composition. Specifically, the composition may be 0.5 wt% to 4 wt%, 0.5 wt% to 3.5 wt%, 0.5 wt% to 3 wt%, 0.5 wt% to 2.5 wt%, 0.5 wt% to 2 wt%, 0.5 wt% to 1.5 wt%, 0.5 wt% to 1 wt%, 1 wt% to 4 wt%, 1 wt% to 3.5 wt%, 1 wt% to 3 wt%, 1 wt% to 2.5 wt%, 1 wt% to 2 wt%, 1 wt% to 1.5 wt%, 2 wt% to 4 wt%, 2 wt% to 3.5 wt%, 2 wt% to 3 wt%, or 2 wt% to 2.5 wt%; more specifically, the DNA fragment mixture may be about 0.5 wt%, about 1 wt%, about 2 wt%, about 3 wt%, or about It may be included in an amount of 4% by weight, but is not limited thereto.
[0049]
[0050] The term "about" above includes not only the exact number specified after the term, but also a range that is approximately that number or close to it. Whether the number is close to or nearly that specific number can be determined by considering the context in which it is presented. For example, the term "about" may refer to a range of -10% to +10% of a numerical value. For another example, the term "about" may refer to a range of -5% to +5% of a given numerical value. For yet another example, it may include, but is not limited to, a range including ±0.5, ±0.4, ±0.3, ±0.2, ±0.1, etc.
[0051] Even if "approximately" is omitted before the numerical value in the present invention, it is obvious that the present invention includes the scope in which it is not omitted.
[0052]
[0053] The term "tissue repair" above may mean improving or repairing tissues such as blood vessels, heart, diaphragm, fascia, skin, joints, joint cavities, cartilage, tendons, or ligaments temporarily or semi-permanently by injecting the composition, or regenerating tissues such as improving contours, forming tissue volume, or healing scars.
[0054] The tissue repair composition of the present invention may be used as a tissue repair material, and said tissue repair material refers to a material used for the replacement, repair, or reconstruction of human tissues and organs such as blood vessels, heart, diaphragm, fascia, skin, joints, joint cavities, cartilage, tendons, or ligaments, and is not limited to cosmetic fillers but may refer to a tissue repair material specified by the Ministry of Food and Drug Safety.
[0055]
[0056] The tissue repair composition according to the present invention may not additionally include high-viscosity dispersants such as carboxymethylcellulose (CMC) or hyaluronic acid (HA). That is, the composition of the present invention is distinguished from the prior art in that it can secure the dispersibility and suspension stability of biodegradable polymer microparticles without a separate polysaccharide-based dispersant.
[0057] Generally, hyaluronic acid-based tissue repair compositions are composed of polysaccharides similar to the components of the human body, resulting in fewer side effects such as skin hypersensitivity reactions. They are easy to administer and remove, and their excellent viscoelasticity makes them advantageous for maintaining skin moisture, volume, and elasticity, making them the most widely used tissue repair compositions currently. Recently, research has been actively conducted to extend the duration of the effect by inducing cross-linking of hyaluronic acid to increase particle size and molecular weight. However, the duration of the effect is typically relatively short, ranging from about 6 to 12 months, which presents the inconvenience of requiring repeated procedures at short intervals to maintain the desired effect.
[0058] In contrast, tissue repair compositions using biodegradable polymers degrade very slowly within the human body, and thus exhibit a relatively long-term maintenance effect compared to hyaluronic acid-based compositions, which are absorbable tissue repair compositions; as a result, they are evaluated and used as semi-permanent tissue repair materials. The composition according to the present invention has technical significance in that it is a tissue repair composition that can secure excellent dispersibility and injectability without using dispersants such as CMC or HA, while utilizing the long-term persistence of such biodegradable polymers.
[0059]
[0060] The tissue repair composition according to the present invention may be characterized by a smaller decrease in pH compared to a composition that does not contain a DNA fragment mixture. Since biodegradable polymers generate acidic degradation products such as lactic acid and glycolic acid as they hydrolyze within the body, the pH of the surrounding environment typically decreases rapidly over time. However, when a DNA fragment mixture is included as in the present invention, buffering capacity and dispersibility are improved even under conditions where the content and type of biodegradable polymer are maintained identically, thereby suppressing the local accumulation of degradation products and mitigating rapid acidification. In one embodiment, when the composition of the present invention and a comparative composition that does not contain a DNA fragment mixture were left in a phosphate buffer solution at 37°C for a certain period and the pH change was measured, it was confirmed that while the comparative composition, which has the same biodegradable polymer composition but does not contain a DNA fragment mixture, showed a rapid decrease in pH after a certain period, the composition of the present invention showed only a gradual decrease compared to the initial pH and maintained a relatively high pH range. This suggests that the composition of the present invention effectively suppresses the rapid acidification that occurs during the degradation process of biodegradable polymers.
[0061]
[0062] Meanwhile, the tissue repair composition according to the present invention may be characterized by a reduced inflammatory response compared to a composition that does not contain a mixture of DNA fragments. Biodegradable polymers can be injected to irritate surrounding tissues, potentially inducing the infiltration of inflammatory cells and chronic inflammatory responses. However, the composition of the present invention can reduce irritation to surrounding tissues, thereby leading to a reduction in tissue reactions. For example, in an animal model, tissues were collected at a certain point after subcutaneous injection of the composition of the present invention and a comparative composition, and H&E staining and image analysis were performed. Consequently, it was observed that the number of inflammatory cells, such as polymorphonuclear leukocytes and lymphocytes, decreased in the group administered the composition of the present invention compared to the group administered the comparative composition. This suggests that the composition of the present invention can favorably mitigate excessive tissue reactions that may accompany the injection of biodegradable polymers.
[0063] The tissue repair composition according to the present invention may be characterized by maintaining uniform homogeneity within a syringe compared to a composition that does not contain a DNA fragment mixture. In conventional biodegradable polymer microparticle formulations, sedimentation and phase separation of particles occur over time, resulting in differences in particle concentration between the upper and lower parts of the syringe and making reproducible administration difficult during injection. In the composition of the present invention, the DNA fragment mixture acts as a water-soluble polymer and a physical support to stabilize the surface of the biodegradable polymer microparticles and suppress aggregation between particles, thereby maintaining a uniformly dispersed suspension of particles within the syringe. In one embodiment, in the present embodiment, the composition of the present invention and the comparative composition were filled into a syringe under the same conditions, and the state of the upper, middle, and lower positions was observed after a certain period of time. As a result, the comparative composition, which has the same biodegradable polymer composition and does not contain a mixture of DNA fragments, showed sedimentation to the bottom and phase separation within a relatively short period of time, whereas the composition of the present invention was confirmed to maintain a homogeneous degree of homogeneity (suspension state) without showing significant sedimentation or layer separation in visual and image analysis during the observation period.
[0064]
[0065] The tissue repair composition according to the present invention may be characterized by reduced nodule or clumping compared to a composition that does not contain a DNA fragment mixture. If biodegradable polymer microparticles aggregate locally or fail to be uniformly distributed after injection, palpable nodules or visible protrusions at the injection site may persist for a long period, which may cause problems in terms of cosmetic and functional aspects. Based on the excellent dispersibility and suspension stability provided by the DNA fragment mixture, the composition of the present invention helps the biodegradable polymer microparticles to be distributed more uniformly upon injection and facilitates the formation of a smooth boundary with the tissue over time. In one embodiment, in an animal experiment of the present embodiment, a comparative composition containing biodegradable polymer microparticles (commercial product (DNA-free)) was injected subcutaneously, and palpation and three-dimensional skin surface analysis were performed for a certain period. As a result, while nodules or protrusions persisted for a long period after injection with the comparative composition, it was confirmed that under the same or similar conditions, the size and height of the nodules formed smaller or decreased more rapidly with the composition of the present invention. These results suggest that the composition of the present invention is advantageous in reducing side effects such as nodules and clumping after the procedure by inducing a uniform distribution of biodegradable polymer microparticles and gradual tissue replacement.
[0066] The tissue repair composition according to the present invention may be characterized by increasing collagen production compared to a composition that does not contain a DNA fragment mixture. By including a DNA fragment mixture, the composition of the present invention alleviates rapid acidification during the degradation process of the biodegradable polymer and excessive inflammatory response caused by the biodegradable polymer, and also maintains the homogeneity (suspension stability) of the formulation, allowing the biodegradable polymer microparticles to be distributed more uniformly at the injection site. Accordingly, it can be understood that the synthesis and / or accumulation of collagen may increase as the tissue reaction at the injection site proceeds more stably. In one embodiment, in one embodiment of the present invention, the tissue repair composition of the present invention and a comparative composition having the same biodegradable polymer composition but not containing a DNA fragment mixture were each treated to a cell or animal model, and the level of collagen production was evaluated. As a result, it was observed that collagen production was significantly increased in the group treated with the composition of the present invention compared to the group treated with the comparative composition.
[0067]
[0068] As such, the tissue repair composition according to the present invention exhibits multiple advantages compared to the same biodegradable polymer composition that does not contain a DNA fragment mixture, including (i) a smaller decrease in pH to suppress rapid acidification, (ii) a reduction in inflammatory response, (iii) excellent suspension stability in a syringe, (iv) a reduction in nodules or clumping after injection, and (v) increased collagen production. Accordingly, the composition of the present invention can be utilized as an effective formulation in the field of tissue repair compositions using biodegradable polymers that is biocompatible and capable of reducing side effects after the procedure.
[0069] Therefore, the composition of the present invention can be advantageously utilized in the field of tissue repair compositions using biodegradable polymers as an effective tissue repair formulation that not only offers excellent biocompatibility and reduces side effects after the procedure, but also achieves long-term tissue repair and cosmetic improvement simultaneously, rather than merely creating volume.
[0070]
[0071] The tissue repair composition according to the present invention may further include one or more compounds selected from the group consisting of anesthetics, polyols, vitamins, amino acids, metals, antioxidants, and mineral salts, but is not limited thereto. In addition, the polyol may be any one selected from the group consisting of diglycerol, erythritol, arabitol, adonitol, sorbitol, mannitol, xylitol, dulcitol, glucose, fructose, xylose, trehalose, maltose, saccharose, and lactose, and specifically may be mannitol, but is not limited thereto.
[0072]
[0073] The tissue repair composition of the present invention provides an injectable composition. The term "injectable" refers to a material having the characteristics required to administer the composition to the dermal region of an individual using an injection device having a fine needle. The fine needle may be appropriately selected by a person skilled in the art to suit the purpose depending on the injection site.
[0074] In the present invention, the term "administration" means introducing the composition of the present invention into an individual by any appropriate method, and the route of administration may be through various routes such as topical application, subcutaneous, dermal, biological membrane, tissue fiber, synovial fluid, etc., as long as the target tissue can be reached. The formulation may be, but is not limited to, a topical preparation, a subcutaneous injection, a dermal injection, an intramuscular injection, an intra-articular injection, a tendon injection, and a ligament injection. The preferred dosage of the composition of the present invention may vary depending on the individual's condition.
[0075]
[0076] The tissue repair composition of the present invention may additionally include any suitable excipients commonly used in the art, such excipients may be, for example, preservatives, wetting agents, dispersants, suspending agents, buffers, stabilizers, or isotonic agents, but are not limited thereto.
[0077]
[0078] Another aspect of the present invention provides a composition for inhibiting or mitigating oxidation of a biodegradable polymer, comprising the tissue repair composition of the present invention as an active ingredient. Specifically, a composition comprising the tissue repair composition of the present invention as an active ingredient can be used to mitigate or delay oxidative stress and resulting oxidative damage that may accompany or be caused by the degradation of the biodegradable polymer.
[0079] The above 'oxidative damage' may include oxidative stress and resulting oxidative damage that may occur in surrounding tissues due to the degradation process of the biodegradable polymer or accompanying changes in the microenvironment after the biodegradable polymer is administered into the body. Additionally, it may include oxidative damage that may occur when the biodegradable polymer itself is exposed to the in vitro environment during the process of storing or handling the composition in various formulation forms, such as syringes or vials (e.g., lyophilized formulations), prior to administration into the body. Accordingly, the composition of the present invention can be used to inhibit or mitigate oxidative damage to the biodegradable polymer not only after administration into the body but also before administration into the body.
[0080] The above term 'inhibition of oxidation or mitigation of oxidation of biodegradable polymers' encompasses a state in which oxidative damage or its progression in the biodegradable polymer and / or the components of the composition is mitigated by reducing oxidative stress that may occur in the microenvironment surrounding the composition during the process in which the biodegradable polymer is degraded within tissues or exposed to the in vivo environment. The composition of the present invention, by including a mixture of DNA fragments, can mitigate microenvironmental changes (e.g., pH reduction) that may accompany the degradation process of the biodegradable polymer, thereby contributing to a reduction in the level of oxidative stress; consequently, it can be understood that the oxidative degradation of the biodegradable polymer and / or the composition may be inhibited or mitigated.
[0081]
[0082] Another aspect of the present invention provides a tissue repair method comprising the step of administering a tissue repair composition of the present invention to an individual.
[0083] Another aspect of the present invention is to provide a method for suppressing rapid acidification and the resulting oxidative stress or inflammatory response caused by individual administration of the tissue repair composition of the present invention.
[0084] The above administration, tissue repair, tissue repair composition, etc. are as described in other embodiments.
[0085] In the present invention, the term "individual" refers to all animals, including humans, rats, mice, livestock, etc., that require or are likely to require tissue repair. Specifically, it may be mammals, including humans.
[0086]
[0087] Another objective of the present invention is to provide a tissue repair use of a composition comprising the tissue repair composition of the present invention.
[0088]
[0089] Another objective of the present invention is to provide a method for preparing a tissue repair composition comprising the following steps (a) to (c):
[0090] (a) a step of preparing a DNA fragment mixture solution by placing a DNA fragment mixture into a solvent and dissolving it at 30°C to 70°C using a heat stirrer;
[0091] (b) a step of adding and mixing a biodegradable polymer to a solution containing the DNA fragment mixture solution while maintaining the solution at 30°C to 70°C; and
[0092] (c) A step of cooling the above-mentioned mixed solution to room temperature.
[0093]
[0094] The solvent of step (a) above may be one or more selected from the group consisting of sterile distilled water, water for injection, sterile physiological saline, and buffer solution. The buffer solution may include, but is not limited to, one or more selected from the group consisting of sodium phosphate monobasic dihydrate, sodium phosphate dibasic dodecahydrate, potassium dihydrogen phosphate, sodium chloride, magnesium chloride, potassium chloride, phosphate buffered saline, HEPES (N-(2-hydroxyethyl)-piperazine-N′-2-ethanesulfonic acid) buffer solution, and mixtures thereof.
[0095] The biodegradable polymer added in step (b) above is added in an amount of 0.5% to 40% by weight based on the total weight of the composition, and the diameter of the biodegradable polymer particles may be 10 μm to 60 μm. The type and content of the biodegradable polymer and the particle diameter range may be applied in the same way as described above.
[0096] After step (c) above, the method may further include a step of drying the mixed solution to produce a solid composition. For example, by additionally applying the mixed solution to a process such as freeze-drying or spray-drying, a tissue repair composition in powder or solid form can be obtained.
[0097] After step (c) above, the method may further include a step of filling a syringe while maintaining the mixed solution in a liquid form. In one embodiment, the mixed solution may be filled into a syringe while maintaining injectable viscosity and dispersibility, and provided as an injectable suspension formulation that can be injected directly into a target tissue, such as the subcutaneous tissue or dermis, upon use.
[0098]
[0099] The manufacturing method according to the present invention has the advantage of efficiently mixing and dispersing a water-soluble phase containing a DNA fragment mixture with a particulate biodegradable polymer, thereby enabling the easy preparation of a tissue repair composition having excellent dispersibility, suspension stability, and injectability without using a separate dispersant such as CMC or hyaluronic acid (HA).
[0100]
[0101] The present invention will be explained in more detail below through examples and experimental examples. However, these examples and experimental examples are intended to illustrate the present invention, and the scope of the present invention is not limited to these examples and experimental examples.
[0102]
[0103] Example 1. Preparation of PN / biodegradable polymer composition
[0104]
[0105] 1-1. Preparation of Buffer Solution
[0106] A phosphate buffer solution was prepared by dissolving sodium phosphate monobasic dihydrate, sodium phosphate dibasic dodecahydrate, sodium chloride, magnesium chloride, potassium chloride, etc., in purified water to adjust the pH to approximately 7.0–7.4. If necessary, one or more buffer solutions selected from the group consisting of phosphate-buffered saline (PBS), physiological saline, HEPES buffer solution, and mixtures thereof were added, or only purified water was used as the solvent.
[0107]
[0108] 1-2. Preparation of PN Solution
[0109] A DNA fragment mixture solution was prepared by adding PN produced by PharmaResearch, a representative example of a DNA fragment mixture, to the above buffer solution and dissolving it while stirring in a heat stirrer set to 30–70°C.
[0110] The content of the DNA fragment mixture was adjusted to be within the range listed in Table 1 (e.g., 0.5 to 4 wt%) based on the total weight of the composition.
[0111]
[0112] 1-3. Preparation of Biodegradable Polymer Suspension
[0113] A biodegradable polymer selected from the group consisting of poly(lactic acid-co-glycolic acid) (PLGA), polylactic acid (PLA; including PLLA and / or PDLLA), polycaprolactone (PCL), and copolymers thereof was added to the above DNA fragment mixture solution.
[0114] The biodegradable polymer used was fine particles manufactured to have an average particle size in the range of about 10 to 60 μm, and was added in an amount of 0.5 to 40 weight percent relative to the total weight of the composition.
[0115] The mixture was thoroughly stirred using a heat stirrer at a temperature of 30 to 70°C to ensure that the biodegradable polymer was uniformly dispersed within the DNA fragment mixture solution.
[0116] The specific composition of each composition (type and content of biodegradable polymer, content of DNA fragment mixture, etc.) is shown in Table 1.
[0117] Type of Biodegradable Polymer Biodegradable Polymer Content (%) DNA Fragment Mixture Content (%) Sample Name (Example) PLGA (PG) 0.50 Comparative Example 1 0.5 Example 12 Example 24 Example 3 10 Comparative Example 22 Example 4 20 Comparative Example 3 0.5 Example 51 Example 62 Example 74 Example 8 400 Comparative Example 4 0.5 Example 92 Example 104 Example 11 PDLLA (PD) 20 Comparative Example 51 Example 122 Example 13 402 Example 17 PLLA (PL) 20 Comparative Example 61 Example 142 Example 15 402 Example 18 PCL (PC) 20 Comparative Example 192 Example 16 402 Example 19--0.5 Comparative Example 71 Comparative Example 82 Comparative Example 94 Comparative Example 10
[0118] 1-4. Comparative Example
[0119] In the comparative example, other dispersants such as hyaluronic acid (HA) and carboxymethylcellulose (CMC) were used instead of PN, and the type and content of the biodegradable polymer were maintained the same (Table 2).
[0120] Dispersant Type Dispersant Content (%) Biodegradable Polymer Type Biodegradable Polymer Content (%) Sample Name (Example) CMC1 PLGA(PG)2 Comparative Example 1 1 2 Comparative Example 12 2 40 Comparative Example 2 0 2 PDLLA(PD)2 Comparative Example 13 2 40 Comparative Example 2 1 2 PCL(PC)2 Comparative Example 14 2 40 Comparative Example 2 2 2 PLLA(PL)2 Comparative Example 2 3 2 40 Comparative Example 2 4 HA1 PLGA(PG)2 Comparative Example 15 2 Comparative Example 16 2 40 Comparative Example 2 5 2 PDLLA(PD)2 Comparative Example 17 2 40 Comparative Example 2 6 2 PCL(PC)2 Comparative Example 18 2 40 Comparative Example 2 7 2 PLLA(PL)2 Comparative Example 28 2 40 Comparative Example 2 9
[0121] 1-5. Formulation
[0122] The above mixed solution was cooled to room temperature and, if necessary, freeze-dried to prepare a solid powder formulation. Alternatively, the above mixed solution was filled directly into a 1 mL syringe to prepare an injectable suspension formulation.
[0123]
[0124] Example 2. Evaluation of the effect of inhibiting rapid acidification according to pH change
[0125]
[0126] Each of the DNA fragment mixture / biodegradable polymer composition prepared in Example 1 and the comparative example composition was placed in a 10 mL vial and stored in a 37°C water bath. The pH was measured using a pH meter immediately after administration (D0), at 1 day (1D), 3 days (3D), 1 week (1W), 2 weeks (2W), and, if necessary, at 3 weeks (3W), 4 weeks (4W), and 6 weeks (6W).
[0127]
[0128] As a result, the compositions of Comparative Examples 1, 2, 3, and 4, which do not contain PN, showed a tendency for excessive acidification due to the hydrolysis of the biodegradable polymer, with the pH decreasing rapidly over time.
[0129] Specifically, in Comparative Example 1 (PG 0.5%), where the biodegradable polymer content was 0.5%, the decrease in pH over time proceeded relatively gradually, whereas in Comparative Examples 2 and 3 (PG 1%, PG 2%), where the content was increased to 1% and 2%, respectively, a relatively larger decrease in pH was observed over the same time interval. In Comparative Example 4 (PG 40%), where the biodegradable polymer content was 40%, the pH decreased more rapidly in the initial stage, and then showed a tendency to be maintained in a low pH range over time, suggesting that acidification may appear more distinctly under conditions of higher polymer content (Figs. 1 to 5).
[0130]
[0131] In contrast, the compositions of Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, and 11 containing PN showed a significantly smaller decrease in pH compared to the comparative example under the same conditions of biodegradable polymer type and content, and tended to maintain a pH above a certain level (Figs. 1 to 5).
[0132] In particular, at the point where the pH of the comparative example without the DNA fragment mixture drops sharply, it can be confirmed that the pH of the composition of the example containing the DNA fragment mixture drops gradually, even though it has the same biodegradable polymer content.
[0133] Specifically, in Comparative Example 1, with a biodegradable polymer content of 0.5% (PG 0.5%), the pH dropped from 6 to 4 after 3 days (3D) and in Comparative Examples 2 and 3, with content of 1% and 2% (PG 1%, PG 2%), the pH dropped to 5 or lower after 3 days (3D), but in Examples 1 to 8, the decrease in pH was relatively small at the same point in time, so the pH remained higher than 6. In the condition where the biodegradable polymer content was 40% (PG 40%), the pH dropped from 7 to 4 in just 1 day (1D), whereas in Examples 9 and 11, the pH remained at 6.
[0134] That is, as shown in FIGS. 1 to 5, it was confirmed that the pH reduction in the present invention containing a DNA fragment mixture is relatively mitigated compared to the examples not containing a DNA fragment mixture under various biodegradable polymer content conditions.
[0135]
[0136] In addition, experimental results showed that the pH decrease tended to be relatively mitigated in the composition containing the DNA fragment mixture even under conditions where the type of biodegradable polymer was different, confirming that the effect of the present invention can be reproduced without being significantly dependent on the type of biodegradable polymer (Figs. 6 to 8).
[0137]
[0138] Example 3. Evaluation of changes in the number of inflammatory cells in an animal model (inhibition of excessive inflammatory response)
[0139]
[0140] A specific dose (e.g., 0.1 mL) of the composition of the example and the composition of the comparative example was injected into the subcutaneous tissue of mice. A certain number of individuals were sacrificed immediately after administration (D0), and at 10, 30, and 60 days (D60) after administration, and tissue samples were collected from the injection site. The collected tissue samples were stained with H&E and observed under a light microscope, and the number of inflammatory cells (e.g., polymorphonuclear leukocytes, lymphocytes, etc.) per specific area was counted.
[0141] As a result, in the group of examples containing a DNA fragment mixture, the number of inflammatory cells was significantly lower compared to the comparative example not containing a DNA fragment mixture and commercial comparative product 1 (Juvelook) and commercial comparative product 2 (Elancé) (Fig. 9). Here, the commercial comparative product is a product that does not contain PN and contains other dispersants and / or biodegradable polymers.
[0142] In addition, as shown in FIG. 4, on day 30 (D30) after administration of formulations of various types of biodegradable polymer compositions, the example containing PN showed a consistent tendency for the number of inflammatory cells to decrease compared to the comparative example not containing PN. This suggests that the inflammatory response alleviating effect due to the inclusion of PN is not limited to a specific type of biodegradable polymer but can be commonly observed for various biodegradable polymers (Fig. 10).
[0143]
[0144] Example 4. Evaluation of dispersibility, injectability, and sedimentation (reduction of nodules / clumping)
[0145]
[0146] 4-1. SEM and cryo-SEM observation
[0147] The compositions of the above examples and comparative examples were freeze-dried to prepare a powder form and observed using SEM. Additionally, the compositions were maintained in a hydrated state and observed using cryo-SEM to confirm the dispersion state of the biodegradable polymer.
[0148] As a result, it was confirmed that in Comparative Example 11 (containing 1% CMC dispersant) and Comparative Example 15 (containing 1% HA dispersant) containing 2% of biodegradable polymer, the distance between biodegradable polymers was very close at a minimum of 1.46 μm, whereas in Example 6 containing a DNA fragment mixture, the distance between biodegradable polymers was more uniformly distributed at a minimum of 18.29 μm (Figs. 11 to 12).
[0149] In addition, compared to Comparative Examples 12 and 16, which each contained 2% of a dispersant, the distance between biodegradable polymers in Example 7 increased from a minimum of 1.31 μm to a minimum of 12.95 μm, confirming that the DNA fragment mixture contained 2% in Example 7, which is more uniformly distributed (Figs. 11 to 12).
[0150] In addition, the size of the PLGA particles was observed using an SEM image with the sample of Comparative Example 12 (a composition containing 2 wt% CMC and 2 wt% PLGA), and the diameter of the PLGA particles was confirmed to be in the range of at least 9.03 μm to a maximum of 61.78 μm (Fig. 13).
[0151]
[0152] 4-2. Measurement of Injection Force
[0153] The compositions of the above examples and comparative examples were filled into a 1 mL syringe and fitted with a 30G or 33G needle. Based on Table 3 below, the injection force was measured at the upper, middle, and lower (1 / 3 point) while pushing the plunger at a constant speed (e.g., 15 mm / min).
[0154] Type and Content of Biodegradable Polymer (%) Injection Rate (mm / min) Needle Type and Content of Dispersant (%) Sample Name PLGA, 0.5 1533 Gnano needle PN, Example 2 2 PLGA, Example 1 4 PLGA, 2 PN, Example 2 7 CMC, Comparative Example 2 1 2 HA, Comparative Example 2 16 PLGA, 4030 Gnano needle PN, Example 2 10 CMC, Comparative Example 2 20 HA, Comparative Example 2 25 PDLLA, 40 PN, Example 2 17 CMC, Comparative Example 2 21 HA, Comparative Example 2 26 PLLA, 40 PN, Example 2 18 CMC, Comparative Example 2 24 HA, Comparative Example 2 29 PCL, 40 PN, Example 2 19 CMC, Comparative Example 2 22HA, 2 Comparative Example 27
[0155] As a result, the example composition containing the DNA fragment mixture showed a small variation in injection force at the upper, middle, and lower positions, indicating high homogeneity of the formulation and excellent injectability (Figs. 14, 15).
[0156] 4-3. Evaluation of Sedimentation (Suspension Stability in Syringe)
[0157] The compositions of the above examples and comparative examples were placed in a 1 mL syringe, and visual images were taken at room temperature at 0 hours, 1 hour, 3 hours, and 24 hours.
[0158] As a result, in the comparative example using HA or CMC as a dispersant, the biodegradable polymer gradually precipitated within 1 to 3 hours, and the supernatant tended to become transparent.
[0159] On the other hand, in the example composition containing a DNA fragment mixture, the biodegradable polymer remained uniformly suspended even after 24 hours, exhibiting excellent dispersion power and suspension stability (Figs. 16 to 24).
[0160] This improvement in dispersibility suggests that it acts as a factor reducing the possibility of nodule / clump formation after injection.
[0161]
[0162] 4-4. Evaluation of Nodules / Clumps in Animal Experiments
[0163] After administering the same amount of the composition subcutaneously to mice, the skin surface was photographed using a PRIMOS CR instrument for up to 60 days. When compared with commercial products (all PN-free), it was confirmed that nodules or protrusions persisted in the commercial products even after 60 days, whereas in the examples containing the DNA fragment mixture, most of the nodules or protrusions disappeared within 60 days (Fig. 25).
[0164]
[0165] Example 5. Evaluation of Collagen Production Ability (Tissue Repair Effect)
[0166] After administering equal amounts of each composition to the subcutaneous tissue of mice, tissue samples were collected at D10, D30, and D60. Masson's trichrome (MT) staining was performed, and the ratio of the collagen stained area to the total tissue area was calculated using image analysis software.
[0167] As a result, under conditions using the same biodegradable polymer, the example containing PN had a higher collagen area ratio compared to the comparative example not containing PN, and furthermore, this trend was commonly observed even when the type of biodegradable polymer changed (Fig. 26). Accordingly, it can be understood that the inclusion of PN can contribute to an increase in collagen production (accumulation) regardless of the type of biodegradable polymer.
[0168] In addition, when compared with commercially available comparative product 1 (Juvelux) and commercially available comparative product 2 (Elancé), higher collagen production capacity was observed in the examples containing DNA fragment mixtures compared to the commercially available products that did not contain DNA fragment mixtures (Fig. 27). In particular, even in examples under conditions where the content of biodegradable polymers differed significantly (e.g., about 20 times), all showed higher collagen density (production capacity) compared to the commercially available products, suggesting that the composition of the present invention is not limited to a specific content and can reproduce tissue repair effects over a wide range of biodegradable polymer content.
[0169]
[0170] From the foregoing description, those skilled in the art to which the present invention pertains will understand that the present invention may be implemented in other specific forms without altering its technical concept or essential features. In this regard, the embodiments described above should be understood as illustrative in all respects and not restrictive. The scope of the present invention should be interpreted as including all modifications or variations derived from the meaning and scope of the claims set forth below and their equivalents, rather than from the detailed description above.
Claims
1. A tissue repair composition comprising a mixture of a biodegradable polymer and a DNA fragment, wherein A tissue repair composition characterized in that the above-mentioned biodegradable polymer is included in an amount of 0.5% to 40% by weight based on the total weight of the composition, and the diameter of the biodegradable polymer particles is 10 μm to 60 μm.
2. A tissue repair composition according to claim 1, characterized in that the DNA fragment mixture is included in an amount of 0.5% to 4% by weight based on the total weight of the composition.
3. A tissue repair composition according to claim 1, characterized in that the amount of pH reduction is smaller compared to a composition that does not contain a mixture of DNA fragments.
4. In Paragraph 1, A tissue repair composition characterized by a reduced inflammatory response compared to a composition that does not contain a mixture of DNA fragments.
5. In Paragraph 1, A tissue repair composition characterized by maintaining uniform homogeneity within a syringe compared to a composition that does not contain a mixture of DNA fragments.
6. In Paragraph 1, A tissue repair composition characterized by reduced nodule or clumping compared to a composition that does not contain a mixture of DNA fragments.
7. In Paragraph 1, A tissue repair composition characterized by increasing collagen production compared to a composition that does not contain a mixture of DNA fragments.
8. In Paragraph 1, A tissue repair composition wherein the above-mentioned biodegradable polymer is one or more selected from the group consisting of polycaprolactone (PL), polylactic acid (PLA), polyglycolic acid (PGA), poly(lactic-co-glycolic acid) (PLGA), poly(dioxanone) (PDS), dioxanone-caprolactone copolymer, lactic acid-caprolactone copolymer, and mixtures thereof.
9. A tissue repair composition according to claim 1, wherein the DNA fragment mixture is one or more selected from the group consisting of polydeoxyribonucleotide, polynucleotide, and mixtures thereof.
10. A tissue repair composition according to claim 1, wherein the DNA fragment mixture has a molecular weight of 50 to 10,000 kDa.
11. A tissue repair composition according to claim 1, wherein the DNA fragment mixture is isolated from the testes or semen of a fish.
12. A tissue repair composition according to claim 11, characterized in that the fish is of the salmon family.
13. A composition for inhibiting or mitigating oxidation of a biodegradable polymer, comprising as an active ingredient a composition according to any one of claims 1 to 12.
14. A method for manufacturing a tissue repair composition according to any one of claims 1 to 12, wherein (a) a step of preparing a DNA fragment mixture solution by placing a DNA fragment mixture into a solvent and dissolving it at 30°C to 70°C using a heat stirrer; (b) a step of adding and mixing a biodegradable polymer to a solution containing the DNA fragment mixture solution while maintaining the solution at 30°C to 70°C; and (c) A method for manufacturing comprising the step of cooling the above-mentioned mixed solution to room temperature.
15. In Paragraph 14, A method for manufacturing, wherein the solvent of step (a) above is one or more selected from the group consisting of sterile distilled water, water for injection, sterile physiological saline, and buffer solution.
16. In Paragraph 15, A method for manufacturing, wherein the above buffer solution comprises one or more selected from the group consisting of sodium phosphate monobasic dihydrate, sodium phosphate dibasic dodecahydrate, potassium dihydrogen phosphate, sodium chloride, magnesium chloride, potassium chloride, and mixtures thereof.
17. In Paragraph 14, A method for manufacturing, wherein the biodegradable polymer added in step (b) is added in an amount of 0.5% to 40% by weight based on the total weight of the composition, and the diameter of the biodegradable polymer particles is 10 μm to 60 μm.
18. In Paragraph 14, A manufacturing method comprising, after step (c), further a step of drying the mixed solution to produce a solid composition.
19. In Paragraph 14, A manufacturing method comprising, after step (c), further a step of filling a syringe while maintaining the mixed solution in a liquid form.
